Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Cancer Immunology ImmunotherapyOpen Access

Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJiarui ZhaoBHBaiyang HuangLMLi Min

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved event-free survival with adjuvant therapy after surgery in NSCLC, highlighting the role of immunotherapy.

Key Points

  • Adjuvant immunotherapy and chemoimmunotherapy significantly improve event-free survival after surgery in resectable NSCLC.
  • Patients receiving immunotherapy or chemoimmunotherapy saw better outcomes than those with no treatment in terms of event-free survival.
  • This retrospective analysis assessed 317 patients over nearly 31 months, with significant findings across various stages and pathologies.
  • Adjuvant therapies may particularly benefit patients without a pathological complete response, suggesting tailored treatment strategies.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/68c23966b210217d6477c409https://doi.org/10.1007/s00262-025-04159-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 25,401 citations